LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy
Out-licensed Assets Aldoxorubicin and Arimoclomol with Strategic Partners
PR Newswire
LOS ANGELES, March 29, 2019